Evidence map›Paper›PMID 40450383›Full record

ArticleMedical physics2025

Actor critic with experience replay-based automatic treatment planning for prostate cancer intensity modulated radiotherapy.

Md Mainul Abrar, Parvat Sapkota, Damon Sprouts, Xun Jia, Yujie Chi

Abstract read
In one paragraph

Article in Medical physics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Md Mainul AbrarDepartment of Physics, The University of Texas at Arlington, Arlington, Texas, USA.
Parvat SapkotaDepartment of Physics, The University of Texas at Arlington, Arlington, Texas, USA.
Damon SproutsDepartment of Physics, The University of Texas at Arlington, Arlington, Texas, USA.
Xun JiaDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland, USA.
Yujie ChiDepartment of Physics, The University of Texas at Arlington, Arlington, Texas, USA.

Funding

Next generation small animal radiation research platformR37CA214639 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI JIA, XUN · 2018 to 2024
$3.8M
Human-like automated radiotherapy treatment planning via imitation learningR01CA254377 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI JIA, XUN, JIANG, STEVE BIN · 2021 to 2025
$2.9M
Intelligent treatment planning for cancer radiotherapyR01CA237269 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI JIA, XUN, JIANG, STEVE BIN · 2019 to 2023
$2.5M
NCI NIH HHS R01 CA237269NCI NIH HHS R01CA237269NCI NIH HHS R01 CA254377NCI NIH HHS R01CA254377NCI NIH HHS R37 CA214639NCI NIH HHS R37CA214639UT system STARs program
6 · The paper itself

Abstract

backgroundAchieving highly efficient treatment planning in intensity-modulated radiotherapy (IMRT) is challenging due to the complex interactions between radiation beams and the human body. The introduction of artificial intelligence (AI) has automated treatment planning, significantly improving efficiency. However, existing automatic treatment planning agents often rely on supervised or unsupervised AI models that require large datasets of high-quality patient data for training. Additionally, these networks are generally not universally applicable across patient cases from different institutions and can be vulnerable to adversarial attacks. Deep reinforcement learning (DRL), which mimics the trial-and-error process used by human planners, offers a promising new approach to address these challenges.  PURPOSE: This work aims to develop a stochastic policy-based DRL agent for automatic treatment planning that facilitates effective training with limited datasets, universal applicability across diverse patient datasets, and robust performance under adversarial attacks.

methodsWe employ an actor-critic with experience replay (ACER) architecture to develop the automatic treatment planning agent. This agent operates the treatment planning system (TPS) for inverse treatment planning by automatically tuning treatment planning parameters (TPPs). We use prostate cancer IMRT patient cases as our testbed, which includes one target and two organs at risk (OARs), along with 18 discrete TPP tuning actions. The network takes dose-volume histograms (DVHs) as input and outputs a policy for effective TPP tuning, accompanied by an evaluation function for that policy. Training utilizes DVHs from treatment plans generated by an in-house TPS under randomized TPPs for a single patient case, with validation conducted on two other independent cases. Both online asynchronous learning and offline, sample-efficient experience replay methods are employed to update the network parameters. After training, six groups, comprising more than 300 initial treatment plans drawn from three datasets, were used for testing. These groups have beam and anatomical configurations distinct from those of the training case. The ProKnow scoring system for prostate cancer IMRT, with a maximum score of 9, is used to evaluate plan quality. The robustness of the network is further assessed through adversarial attacks using the fast gradient sign method (FGSM).

resultsDespite being trained on treatment plans from a single patient case, the network converges efficiently when validated on two independent cases. For testing performance, the mean

conclusionsWe successfully trained a DRL agent using the ACER technique for high-quality treatment planning in prostate cancer IMRT. It achieves high generality across diverse patient datasets and exhibits high robustness against adversarial attacks.

Indexed as

Prostatic NeoplasmsRadiotherapy, Intensity-ModulatedRadiotherapy Planning, Computer-AssistedAutomationDeep LearningHumansMaleartificial intelligenceautomatic treatment planningreinforcement learning

Identifiers

PMID40450383
PMCPMC12258009

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.